Takeda TSE4502NYSETAK today announced that the Japanese Ministry of Health Labour and Welfare has approved the use of CUVITRU Immune Globulin Subcutaneous Human 20 Solution in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia1.